Studies of tirzepatide and cholesterol show a modest drop in the cholesterol linked to artery buildup, with larger changes in other blood fats. That can help explain a lab report, but it doesn't turn tirzepatide into a cholesterol medicine. It doesn't replace a statin, a medicine prescribed to lower cholesterol.
The useful question is which number changed, by how much, and whether it reached the goal set by the treating doctor.
Tirzepatide and cholesterol: the four lab numbers
A lipid panel—a blood test measuring cholesterol and other fats—usually lists these results:
| Lab result | What it means |
|---|---|
| LDL cholesterol | Carries cholesterol that can build up in arteries |
| HDL cholesterol | Helps carry cholesterol back to the liver for removal |
| Triglycerides | A separate type of blood fat used for energy |
| Non-HDL cholesterol | Total cholesterol minus HDL; includes LDL and other particles linked to artery buildup |
MedlinePlus explains the four readings. Non-HDL isn't a fifth test: a total cholesterol of 205 minus an HDL of 45 gives a non-HDL of 160.
Most U.S. reports use mg/dL, meaning milligrams per deciliter, a measure of concentration in blood. A percentage change describes how far a result moved from its starting value.
SURMOUNT-1 lipid results by dose
SURMOUNT-1, published in the New England Journal of Medicine in 2022, followed 2,539 adults with obesity or overweight without diabetes for 72 weeks. Participants received weekly tirzepatide injections or placebo, an injection without the study medicine. Both groups received food and activity counseling.
Weight change was the main question. Lipid changes were secondary endpoints, extra measurements beyond that main question.
As of September 30, 2026, the day this article was written, the Zepbound prescribing information carries “Revised: 08/2026.” Its Table 3 reports these changes in the SURMOUNT-1 population:
| Average change from the starting level at week 72 | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Placebo |
|---|---|---|---|---|
| LDL | −4.6% | −5.6% | −7.1% | −1.7% |
| HDL | +6.9% | +9.2% | +8.0% | −0.7% |
| Triglycerides | −21.2% | −23.8% | −29.1% | −5.6% |
| Non-HDL | −8.0% | −9.4% | −11.7% | −2.3% |
Minus means a decrease; plus means an increase. These are percentage changes within each group, not mg/dL changes or reductions after subtracting placebo. The label's analysis includes everyone assigned to treatment, with estimates for missing readings. At 5 mg, uncertainty around the LDL comparison still included no difference from placebo.
What does a small LDL drop look like?
Here is illustrative arithmetic using the label's 7.1% average LDL reduction in the 15 mg group. Starting at 130 mg/dL:
130 × 0.071 = 9.2 mg/dL lower; 130 − 9.2 = about 120.8 mg/dL.
For comparison, that group's 29.1% average triglyceride reduction applied to an illustrative 200 mg/dL reading gives:
200 × 0.291 = 58.2 mg/dL lower; 200 − 58.2 = about 141.8 mg/dL.
Those starting values are examples, not trial averages or predictions. A drop of about nine LDL points may still leave a person above their treatment goal. A trial percentage doesn't tell a doctor that another cholesterol medicine is unnecessary.
What SURPASS found in people with diabetes
The SURPASS program studied tirzepatide in type 2 diabetes, a condition in which blood sugar stays too high. A 2025 analysis in the Journal of the American College of Cardiology combined seven trials involving 7,805 people, with roughly 41 weeks of treatment.
Compared with placebo or other diabetes medicines, tirzepatide was associated with lower odds of high triglycerides and low HDL. Here, “odds” compares how often a result met that definition with how often it didn't. It doesn't describe a percentage change in the blood reading itself.
That supports the broader pattern, but it isn't the same population or comparison as SURMOUNT-1. Diabetes trial results don't supply a personal LDL forecast either.
What September's everyday-care study found
As of September 30, 2026, the day this article was written, a Mayo Clinic study published September 9 in the Journal of the Endocrine Society adds a useful reality check. Researchers reviewed records from 1,028 adults who used tirzepatide continuously for at least a year; about three-quarters had type 2 diabetes.
Among those with paired blood readings, triglycerides fell an average 8.5% and HDL rose 11.3%. LDL changed by −1.2%, without a statistically clear change—meaning the study couldn't distinguish that small shift from chance variation.
This was a records review without a comparison group. It shows an association, not how much change the medicine alone caused. Compounded products, medicines prepared by a pharmacy for a prescription, were excluded. The LDL finding is a reason to keep checking the actual lab result rather than assume it improved with weight.
Why better numbers don't replace a statin
Tirzepatide isn't a cholesterol drug and doesn't replace a statin a doctor prescribed. Cholesterol treatment has its own goals. The American Heart Association's current guideline summary ties LDL and non-HDL goals to a person's heart and blood-vessel risk.
A better lipid panel also isn't the same measurement as fewer heart attacks or strokes. Trials have to count those events separately.
As of September 30, 2026, the day this article was written, the FDA's August 27 action letter for Mounjaro adds a use for reducing heart attack, stroke and death from heart or blood-vessel disease in adults with type 2 diabetes at high risk. That is a brand-specific use, not an instruction to replace cholesterol treatment. Our guides to tirzepatide heart benefits and SURPASS-CVOT results explain the heart evidence and its limits.
How does semaglutide compare for cholesterol?
As of September 30, 2026, the day this article was written, an analysis published September 28 in the International Journal of Obesity compares tirzepatide doses with semaglutide 2.4 mg. It uses two separate trials linked through their placebo groups, rather than a new trial assigning people to either medicine.
The analysis favored tirzepatide for HDL increases, and the 15 mg dose for triglyceride reductions. It didn't establish a clear LDL advantage. The study was funded by tirzepatide's manufacturer.
That is context for the conversation, not a ranking of cholesterol medicines. Tirzepatide versus semaglutide covers the direct comparisons for weight and blood sugar.
What belongs in the follow-up conversation
A useful review compares the starting lipid panel with repeat readings, the doctor's cholesterol goal, and any changes in other medicines. The LDL goal still matters even when weight or triglycerides improve. Treatment changes belong with the clinician managing that goal.
The questions are concrete: What LDL goal fits my history? Who is managing cholesterol treatment? When will the panel be repeated? What happens if weight changes but LDL doesn't?
Earlier lab reports, family history of early heart disease, diabetes, and current medicines help put a result in context. A reviewing provider needs that context before deciding what the next reading means. That review keeps the cholesterol goal connected to the rest of the treatment plan.
Through Promise, tirzepatide and semaglutide are dispensed as compounded medications, which are different from an FDA-approved product: the formulations offered here are not FDA-approved. The branded-injection trial figures aren't measurements of Promise's formulations.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.
